

03 Jun 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: ASCO preview; Asahi Kasei's US acquisition; Novartis aims for renal disease dominance; paying for gene therapies; and US BIOSECURE Act diluted.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 31 May 2024, including: ASCO preview; [Asahi Kasei Corporation](#)'s US acquisition; [Novartis AG](#) aims for renal disease dominance; paying for gene therapies; and US BIOSECURE Act diluted.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[ASCO Preview: Five Presentations To Watch Out For](#)" - Scrip, 23 May, 2024.)

(Also see "[Asahi Kasei Furthers Its US, Health Care Growth With \\$1.1bn Calliditas Buy](#)" - Scrip, 28 May, 2024.)

(Also see "[Novartis Aims To Dominate Rare Renal Disorders](#)" - Scrip, 25 May, 2024.)

(Also see "[Could Combining Strategies Be A Way Forward To Pay For Gene Therapies?](#)" - Scrip, 28 May, 2024.)

(Also see "[BIOSECURE Act Diluted Significantly, But China Plus Strategy Still Accelerating: Strides](#)" - Scrip, 28 May, 2024.)

MD" - Scrip, 24 May, 2024.)

[Click here to explore this interactive content online](#) ✨